Knight Therapeutics (GUD) Sets New 12-Month Low at $7.27

Knight Therapeutics Inc (TSE:GUD)’s share price hit a new 52-week low on Monday . The stock traded as low as C$7.27 and last traded at C$7.33, with a volume of 81800 shares trading hands. The stock had previously closed at C$7.35.

Separately, Raymond James set a C$10.25 price target on Knight Therapeutics and gave the company an “outperform” rating in a report on Friday, March 15th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of C$10.06.

The firm has a market cap of $1.05 billion and a PE ratio of 43.39.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings results on Thursday, March 14th. The company reported C$0.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of C$0.03 by C$0.01. The business had revenue of C$3.89 million during the quarter, compared to the consensus estimate of C$2.55 million. On average, equities research analysts anticipate that Knight Therapeutics Inc will post 0.180000017349399 EPS for the current fiscal year.

In other news, Director Jonathan Ross Goodman acquired 3,600 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was purchased at an average cost of C$7.38 per share, for a total transaction of C$26,568.00. Following the completion of the transaction, the director now directly owns 444,320 shares in the company, valued at C$3,279,081.60.

COPYRIGHT VIOLATION WARNING: “Knight Therapeutics (GUD) Sets New 12-Month Low at $7.27” was first posted by PressOracle and is the property of of PressOracle. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at

About Knight Therapeutics (TSE:GUD)

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

See Also: Swap

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with's FREE daily email newsletter.